All In Biotech

Drug Trial Radar · NCT05412030

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy Infants

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 388 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

388

Actual

Start

Jun 16, 2022

Primary completion

Sep 18, 2025

Study completion Sep 18, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 90 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 (PCV20). Part 1 is the dose-escalation lead-in portion of the study, in which infants at each dose level are randomized 3:1 in sequential cohorts to receive increasing doses of AFX3772 or PCV13. In Part 2, infants are randomized to receive either one of two dose levels of AFX3772 or PCV20. On 31 October 2024, the study was placed on partial clinical hold by the U.S. Food and Drug Administration. The hold was not related to safety concerns in participants who had already received the study vaccines. As a result, enrollment was paused and no further doses of the investigational pneumococcal vaccine were administered. Participants who were already enrolled transitioned to the standard of care pneumococcal vaccine to complete their scheduled visits through post-dose 3 and subsequently completed study follow-up.

Conditions

  • Pneumonia, Bacterial
  • Pneumococcal Infections
  • Pneumonia, Pneumococcal

Interventions

  • AFX3772Biological

    AFX3772 administered intramuscularly.

  • Prevnar 13Biological

    PCV13 administered intramuscularly.

  • Prevnar 20Biological

    PCV 20 administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Any Solicited Injection Site Adverse Events (AEs) After First DoseTime frame: Day 1 to Day 7 post dose 1
  2. Number of Participants Reporting Any Solicited Injection Site AEs After Second DoseTime frame: Day 1 to Day 7 post dose 2
  3. Number of Participants Reporting Any Solicited Injection Site AEs After Third DoseTime frame: Day 1 to Day 7 post dose 3
  4. Number of Participants Reporting Any Solicited Systemic Events After First DoseTime frame: Day 1 to Day 7 post dose 1
  5. Number of Participants Reporting Any Solicited Systemic Events After Second DoseTime frame: Day 1 to Day 7 post dose 2
  6. Number of Participants Reporting Any Solicited Systemic Events After Third DoseTime frame: Day 1 to Day 7 post dose 3
  7. Number of Participants Reporting Any Unsolicited AEsTime frame: Within 30 days post each dose (at 2, 4, and 6 months of age as part of primary vaccination series)
  8. Number of Participants Reporting Any Serious Adverse Events (SAEs)Time frame: Day 1 through 6 months post dose 3

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Gardena, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Madera, California

  • GSK Investigational Site

    Ontario, California

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Pensacola, Florida

  • GSK Investigational Site

    Saint Augustine, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Bardstown, Kentucky

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Covington, Louisiana

  • GSK Investigational Site

    Haughton, Louisiana

  • GSK Investigational Site

    Lafayette, Louisiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Mankato, Minnesota

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    Hastings, Nebraska

  • GSK Investigational Site

    Norfolk, Nebraska

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Tulsa, Oklahoma

  • GSK Investigational Site

    Cranberry Township, Pennsylvania

  • GSK Investigational Site

    Jefferson Hills, Pennsylvania

  • GSK Investigational Site

    N. Huntingdon, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Brownsville, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Dickinson, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Houston, Texas

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.